Lung cancer remains the most frequent cause of cancer-related deaths worldwide. Our Unit focuses on the study of lung cancer with a pragmatic bench-to-bedside orientation, aiming to solve the problems of lung cancer patients. We specialise in two research areas: the identification of novel molecular biomarkers for diagnostic, prognostic, and predictive purposes, and the development of advanced targeted and immunotherapeutic strategies.
We have made significant progress in understanding the disease, developing an extensive platform of patient-derived xenografts (PDXs) and organoids (PDOs) of non-small-cell and small-cell lung cancers to evaluate emerging therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs (tarlatamab, the combination of lurbinectedin and atezolizumab, pemetrexed, and others) to the clinic, as well as in conducting practice-changing trials in the fields of personalised cancer care and immuno-oncology.
Open Access